SCHEDULE: FMR LLC Discloses Stake in Dyne Therapeutics

FMR LLC has reported beneficial ownership of 5.4% of Dyne Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson and other affiliated entities, has filed a Schedule 13G indicating beneficial ownership of Dyne Therapeutics Inc. common stock.
• The filing, dated March 31, 2026, shows FMR LLC beneficially owns 8,908,979.89 shares, representing 5.4% of the class of securities.
• Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, and a predominant owner of Series B voting common shares, may be deemed to control FMR LLC.
• The filing is made in accordance with Rule 13d-1(b) and indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a significant investment by a major player, which can be positive, but it does not offer operational updates or performance data for Dyne Therapeutics itself.

Positives

• FMR LLC, a significant investment management firm, has taken a notable stake in Dyne Therapeutics, potentially signaling confidence in the company's prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Risks

• While not explicitly stated as a risk in this filing, any significant change in beneficial ownership by large institutional investors can sometimes precede or coincide with shifts in company strategy or market perception.
• The filing does not provide details on the specific investment strategy or rationale behind acquiring this stake, leaving room for speculation about future actions.

Future Outlook

This filing does not contain forward-looking statements or guidance from Dyne Therapeutics Inc. It solely reports on the beneficial ownership of FMR LLC.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by a major institutional investor like FMR LLC is a common event in the biotechnology sector, often indicating a significant investment position. Dyne Therapeutics operates in the gene therapy space, a highly competitive and capital-intensive industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by FMR LLC may be viewed positively by existing shareholders, potentially indicating increased institutional interest and confidence in the company.
• Management and Board of Directors: The filing confirms FMR LLC's investment strategy is not aimed at influencing control, which provides clarity to Dyne Therapeutics' leadership.

Next Steps

• FMR LLC will continue to hold its beneficial ownership of Dyne Therapeutics Inc. common stock.
• Dyne Therapeutics Inc. will continue its operations and business activities as previously disclosed.

Key Dates

Keywords

Dyne Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Abigail P. Johnson